Previously Undetected Obstructive Sleep Apnea in Patients With New-Onset Atrial Fibrillation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 09 07 2020
revised: 24 09 2020
accepted: 28 09 2020
pubmed: 16 10 2020
medline: 2 2 2021
entrez: 15 10 2020
Statut: ppublish

Résumé

Obstructive sleep apnea-hypopnea syndrome (OSA) compromises the efficacy of atrial fibrillation (AF) control strategies. Continuous positive airway pressure (CPAP) may ameliorate arrhythmia control especially in early AF stages (new-onset AF). We investigated a practical screening strategy to determine the likelihood of CPAP indication in new-onset AF patients. Seventy-seven consecutive patients with new-onset (<1 month) AF were prospectively evaluated. Of them, 4 were excluded due to previously diagnosed OSA. The remaining 73 (68% persistent AF) fulfilled the Epworth, Berlin and STOP-BANG questionnaires, an ambulatory polysomnography being performed thereafter in all them in order to determine the apnea-hipopnea index (AHI). CPAP was indicated following conventional criteria. The variables associated with the diagnosis of OSA, with the AHI value and with CPAP indication were investigated by means of descriptive, univariate and multivariate analysis. The prevalence of OSA of any degree and CPAP indication was 82% and 37%, respectively. The variables associated (p < 0.05) with a higher AHI were male gender, body mass index, obesity, hypertension, and high-risk scoring at the Berlin and STOP-BANG questionnaires. In the multivariate analysis, the STOP-BANG scoring proved superior to conventional risk factors and became the only variable predicting CPAP indication (odds ratio 4.5 [1.9 to 10.6]; p = 0.01), an optimized cutoff value of ≥4 being newly established (sensitivity/specificity 76/65%). In conclusion, in patients referred with new-onset AF we documented a high risk of OSA and of need for CPAP. A STOP-BANG scoring of ≥4 in our population was a practical screening alternative to direct polysomnography in this setting.

Identifiants

pubmed: 33058803
pii: S0002-9149(20)31092-4
doi: 10.1016/j.amjcard.2020.09.058
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-52

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Victor Bazan (V)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain. Electronic address: victorbazang@yahoo.com.

Ignacio Vicente (I)

Respiratory Medicine Department, Hospital Universitari Germans Trias i Pujol, Madrid, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Lourdes Lozano (L)

Respiratory Medicine Department, Hospital Universitari Mútua de Terrassa. Universitat de Barcelona. Barcelona, Spain.

Roger Villuendas (R)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Marta González (M)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Raquel Adeliño (R)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Felipe Bisbal (F)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Axel Sarrias (A)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Jorge Abad (J)

Respiratory Medicine Department, Hospital Universitari Germans Trias i Pujol, Madrid, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

José Sanz-Santos (J)

Respiratory Medicine Department, Hospital Universitari Mútua de Terrassa. Universitat de Barcelona. Barcelona, Spain.

Ferran Padilla (F)

Cardiology Department, Hospital Universitari Mútua de Terrassa, Barcelona, Spain.

Antoni Bayés-Genís (A)

Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBERCV, Ciber de Enfermedades Respiratorias, Madrid, Spain. Universitat Autonoma de Barcelona. Barcelona. Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH